GGrantIndex
Sort

39,280 grants matching leukemia

Stanford University NCTN- Network Lead Academic Site

$576,471
Heather Ann Wakelee · Stanford University · U10 · FY2014 · CA

ITIM-receptors for cancer treatment

$576,447
Chengcheng Zhang · Ut Southwestern Medical Center · R01 · FY2021 · CA

Using the Preimplantation Factor (PIF) to Treat Graft-versus-Host Disease

$576,445
Asaf Alimardanov · National Center For Advancing Translational Sciences · ZIA · FY2019 · TR

Molecular Genetics of CLL

$576,406
Carlo M Croce · University Of California, San Diego · P01 · FY2009 · CA

Project 1: Effects of inflammation on clonal competition and malignant transformation

$576,281
Katherine Yudeh King · Baylor College Of Medicine · P01 · FY2023 · CA

Specific Adoptive Immunotherapy of Leukemia

$576,225
Philip D Greenberg · Fred Hutchinson Cancer Research Center · P01 · FY2008 · CA

Lentiviral Gene Therapy and Genome Editing for X-linked Severe Combined Immunodeficiency

$576,217
Stephen Gottschalk · St. Jude Children'S Research Hospital · P01 · FY2020 · HL

Lentiviral Gene Therapy and Genome Editing for X-linked Severe Combined Immunodeficiency

$576,217
Stephen Gottschalk · St. Jude Children'S Research Hospital · P01 · FY2022 · HL

Lentiviral Gene Therapy and Genome Editing for X-linked Severe Combined Immunodeficiency

$576,217
Stephen Gottschalk · St. Jude Children'S Research Hospital · P01 · FY2021 · HL

GENETIC EPIDEMIOLOGY OF CHRONIC LYMPHOCYTIC LEUKEMIA

$576,213
Nicola J Camp · University Of Utah · R01 · FY2010 · CA

Single Cell Methods for Bioeffector Discovery and Analysis

$576,206
Brian O Bachmann · Vanderbilt University · R01 · FY2023 · CA

Heartland Cancer Research CCOP

$576,180
Alan P Lyss · Missouri Baptist Medical Center · U10 · FY2009 · CA

Novel Biomarkers to Risk-Stratify AML Patients with NPM1^Pos/FLT3-IT^Neg Genotype

$576,165
Derek L Stirewalt · Fred Hutchinson Cancer Research Center · R01 · FY2016 · CA

Ezh2-mediated Epigenetic Effects and Alloimmunity

$576,162
Yi Zhang · Temple Univ Of The Commonwealth · R01 · FY2019 · HL

Genetic Consequences of Therapies for Cancer

$575,969
John Dunning Boice · Vanderbilt University · R01 · FY2008 · CA

BIOINFORMATICS SHARED RESOURCE

$575,740
Jennifer S. Shoemaker · Duke University · P30 · FY2009 · CA

Determining the Role and Targeting potential of Serine Metabolism in aggressive sub-types of Acute Myeloid Leukemia

$575,727
Stephen Matthew Sykes · Washington University · R01 · FY2023 · CA

Quality of Life of African American Cancer Survivors

$575,644
University Of Illinois At Chicago · R01 · FY2003 · CA

Stem Cells, Differentiation and Therapeutic Resistance in AML

$575,611
Martin Carroll · University Of Pennsylvania · R01 · FY2014 · CA

Collaborative Pathways that Lead to Leukemia

$575,510
Peter Aplan · Division Of Basic Sciences - Nci · ZIA · FY2025 · CA

Pre-clinical Studies of Therapy for Myelodysplastic Syndrome

$575,510
Peter Aplan · Division Of Basic Sciences - Nci · ZIA · FY2025 · CA

Mutation Mechanisms Leading to Malignant Transformation, Including Chromosomal Translocation and Point Mutations

$575,510
Peter Aplan · Division Of Clinical Sciences - Nci · ZIA · FY2025 · CA

A rapid spontaneous murine model of CN-AML

$575,500
H Leighton Grimes · Cincinnati Childrens Hosp Med Ctr · R01 · FY2017 · CA

Translational Pathology Core

$575,479
Sue Ellen Martin · University Of Southern California · P30 · FY2022 · CA

Improving risk allocation and developing novel therapies for children with T-ALL

$575,456
David T. Teachey · Children'S Hosp Of Philadelphia · R01 · FY2019 · CA